As part of the dialogue with the pharmaceutical industry, the German government has promised to introduce the option of a confidential reimbursement amount. The aim is to support pharmaceutical companies whose products are subject to a considerable price decrease after undergoing an AMNOG benefit assessment by offering the option to keep the new price confidential.
The German Federal Ministry of Health has published a draft law on the financial stabilization of the statutory health insurance (GKV-FinStG). The subjects of the draft are amendments to the Social Code Book V, in particular Articles § 35 a and § 130 b, which include the early benefit assessment of new active substances and
WS Value & Dossier GmbH
Your specialists for market access and reimbursement.
Rheinstr. 2
65760 Eschborn
Germany
phone: +49 6173 3941016
fax: +49 6173 39411021
© Copyright 2024 | WS Value Dossier GmbH